Loading...
NPI 1710074885 · New York, NY · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ruben Niesvizky is a hematology & oncology physician provider located in New York, New York. This profile covers 20 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Ruben Niesvizky |
| Address | 425 E 61st St Fl 8 |
| City | New York |
| State | NY |
| ZIP | 10065 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | October 9, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $12.4K |
Medicare dominates this provider’s payor mix: the provider reported Total Medicare revenue of $3.1M versus Total Medicaid revenue of $12.4K, indicating Medicare is the overwhelmingly primary payer for clinical activity and drug administration in this practice. Medicaid activity is present but de minimis in scale compared with Medicare.
Medicare revenue is highly concentrated in a few infusion/drug codes: the top 3 Medicare codes by revenue (J9144, J1568, J1561) account for 83.0% of the provider’s total Medicare revenue, with J9144 contributing $1.8M, J1568 $453.6K, and J1561 $250.4K. This concentration signals that a small set of biologic/infusion products drives the vast majority of billings.
The code mix points to an oncology infusion and supportive-care operation: J9144 (daratumumab with hyaluronidase), high-volume IV/SC immune globulins (J1568, J1561), and chemotherapy administration codes like 96401 and 96413 appear in the top codes, implying on-site administration of specialty oncology drugs alongside outpatient management of hematology/oncology patients. The presence of both high-volume drug codes and E/M codes suggests integrated clinical visits paired with drug delivery.
The provider is a national-volume outlier for specific injectable therapies: J9144 ranks #2 of 615 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code) and J9041 ranks #4 of 357 providers nationally (99th percentile; extreme outlier). These rankings indicate unusually high national-scale throughput for select high-cost or frequently administered oncology injectables.
High-complexity outpatient care is a material part of revenue: 99215 accounts for $141.8K of Medicare revenue from 909 claims and ranks #364 of 145531 providers nationally (100th percentile; extreme outlier). This suggests substantial volumes of high-complexity established-patient visits, consistent with ongoing management of complex oncology patients.
Medicaid revenue is narrowly concentrated and modest: the top Medicaid code 99215 accounts for 100.0% of this provider’s total Medicaid revenue ($12.3K from 132 claims) and ranks #842 of 2046 providers in-state (59th percentile). In-state Medicaid activity appears limited to outpatient established-patient visits rather than high-volume infusion billing.
Several Medicare-administered infusion codes show above-typical national activity: 96401 ranks #168 of 3868 providers (96th percentile; notably above typical national volume for this code) and other administration codes like 96365/96366 also rank in higher percentiles. These patterns reinforce that the practice performs substantial onsite drug administration beyond routine office visits.
Tenure and stability: the NPI was enumerated on 2006-10-09 (~20 years ago), indicating long-term presence in the market. Combined with the concentrated Medicare drug volumes, the provider appears to maintain an established infusion-focused hematology/oncology practice in New York, with potential sensitivity to changes in utilization or reimbursement for the small set of revenue-driving biologics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 48,420 | $40 | $1.8M |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13,340 | $30 | $453.6K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6,590 | $40 | $250.4K |
| J0897 | Injection, denosumab, 1 mg | 8,400 | $20 | $151.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 910 | $160 | $141.8K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 670 | $70 | $47K |
| J9041 | Injection, bortezomib, 0.1 mg | 11,220 | $1 | $44.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 350 | $110 | $39.4K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 370 | $60 | $22.7K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11,100 | $1 | $22.2K |
Showing 1–10 of 20
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
20 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9144 | 1 | 20 | 10,440 | $40 | $499.4K |
| J1561 | 12 | 40 | 3,100 | $40 | $234.9K |
| J1568 | 1 | 30 | 2,880 | $30 | $113.4K |
| J0897 | 68 | 490 | 2,820 | $20 | $84.4K |
| J0881 | 51 | 80 | 13,100 | $1 | $41K |
| 99214 | 4,860 | 30,450 | 90 | $100 | $19K |
| 96413 | 205 | 380 | 110 | $110 | $18.1K |
| 99233 | 7,514 | 8,640 | 80 | $100 | $15.8K |
| 99232 | 4,884 | 11,850 | 80 | $70 | $13.8K |
| J9041 | 1 | 20 | 2,420 | $1 | $12.9K |
Showing 1–10 of 20
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 130 | $90 | $12.3K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 210 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 842 | 2,050 | 90 | $140 | $121.2K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 3,082 | 5,090 | 450 | $10 | $35.9K |
Other providers in the same ZIP code as Ruben Niesvizky, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| The New York And Presbyterian Hospital | NY | General Acute Care Hospital | $276.3K | $207.4M |
| Memorial Hospital For Cancer And Allied Diseases | NY | General Acute Care Hospital | $0 | $135.1M |
| Rami Sartawi | NY | Vascular & Interventional Radiology Physician | $3.7M | $4.9M |
| Sherif Heiba | NY | Nuclear Medicine Physician | $1.7M | $18.5K |
| Gregory Harmon | NY | Ophthalmology Physician | $1.4M | $54.2K |
| David Fox | NY | Vascular Surgery Physician | $859K | $77.5K |
| Mark Francescone | NY | Diagnostic Radiology Physician | $824K | $6.3K |
| Matthew Agee | NY | Diagnostic Radiology Physician | $740.7K | $4.3K |
| Lily Zou | NY | Diagnostic Radiology Physician | $714.5K | $0 |
| Sarah Choxi | NY | Anesthesiology Physician | $652.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.